Novo Nordisk A/S
NOVA.STU
| Exchange: | STU |
| Currency | Euro |
| ISIN: | US6701002056 |
| LEI: | 549300DAQ1CVT6CXN342 |
| Primary Ticker: | NOVO-B.CO |
| Fiscal Year End: | December |
| Updated On: | 2024-11-03 |
Highlights
| Market Capitalization: | 230198405301 |
| Market Capitalization Mln: | 230198.40 |
| PEG Ratio: | 1.72 |
| Dividend Yield: | 0.02 |
| Most Recent Quarter: | 2024-06-30 |
Valuation
| Forward PE: | 28.01 |
| Price Sales TTM: | 13.39 |
| Price Book MRQ: | 30.53 |
| Enterprise Value: | 457942745905 |
| Enterprise Value Revenue: | 13.24 |
| Enterprise Value Ebitda: | 25.50 |
Technicals
| 52 Week High: | 138.92 |
| 52 Week Low: | 86.16 |
| 50 Day MA: | 112.5 |
| 200 Day MA: | 118.43 |
Splits & Dividends
| Forward Annual Dividend Yield: | 0.02 |
| Last Split Factor: | 2:1 |
| Last Split Date: | 2023-09-20 |
Earnings
| Report Date: | 2025-04-30 |
| Date: | 2025-03-31 |
| Before After Market: | Before Market |
| Currency: | DKK |
| Report Date: | 2025-02-05 |
| Date: | 2024-12-31 |
| Before After Market: | Before Market |
| Currency: | DKK |
| Report Date: | 2024-11-06 |
| Date: | 2024-09-30 |
| Before After Market: | Before Market |
| Currency: | DKK |
| Date: | 2024-09-30 |